gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Phosphodiesterase 9A

PDE9A, phosphodiesterase 9A, PDE9A1
The protein encoded by this gene catalyzes the hydrolysis of cAMP and cGMP to their corresponding monophosphates. The encoded protein plays a role in signal transduction by regulating the intracellular concentration of these cyclic nucleotides. Multiple transcript variants encoding several different isoforms have been found for this gene. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: Phosphodiesterase, PDE, PDE8A, HAD, PDE5
Papers on PDE9A
Inhibition of PDE2A, but not PDE9A, modulates presynaptic short-term plasticity measured by paired-pulse facilitation in the CA1 region of the hippocampus.
Kroker et al., Biberach an der Riß, Germany. In Synapse, Oct 2015
Inhibitors of PDE2A and PDE9A have emerged as potential candidates shown to improve synaptic plasticity and memory function in animals.
Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease.
Kass et al., Baltimore, United States. In Nature, Apr 2015
Here we show that cGMP-selective PDE9A (refs 7, 8) is expressed in the mammalian heart, including humans, and is upregulated by hypertrophy and cardiac failure.
Molecular dynamics-based discovery of novel phosphodiesterase-9A inhibitors with non-pyrazolopyrimidinone scaffolds.
Luo et al., Guangzhou, China. In Mol Biosyst, 2015
Phosphodiesterase-9A (PDE9A) is a promising therapeutic target for the treatment of diabetes and Alzheimer's disease (AD).
Application of neurophysiological biomarkers for Huntington's disease: evaluating a phosphodiesterase 9A inhibitor.
Hajós et al., New Haven, United States. In Exp Neurol, 2015
Systemic administration of the recently developed phosphodiesterase 9A (PDE9A) inhibitor PF-04447943 dose-dependently improved gating deficit in transgenic BACHD rats in both brain regions.
(±)-Torreyunlignans A-D, rare 8-9' linked neolignan enantiomers as phosphodiesterase-9A inhibitors from Torreya yunnanensis.
Yin et al., Guangzhou, China. In J Nat Prod, 2015
The compounds were screened by using tritium-labeled adenosine 3',5'-cyclic monophosphate ([(3)H]-cGMP) as a substrate for inhibitory affinities against phosphodiesterase-9A (PDE9A), which is a potential target for the treatment of diabetes and Alzheimer's disease.
Discovery of a phosphodiesterase 9A inhibitor as a potential hypoglycemic agent.
Luo et al., Guangzhou, China. In J Med Chem, 2015
Phosphodiesterase 9 (PDE9) inhibitors have been studied as potential therapeutics for treatment of diabetes and Alzheimer's disease.
Validation of PDE9A Gene Identified in GWAS Showing Strong Association with Milk Production Traits in Chinese Holstein.
Sun et al., Beijing, China. In Int J Mol Sci, 2014
Phosphodiesterase9A (PDE9A) is a cyclic guanosine monophosphate (cGMP)-specific enzyme widely expressed among the tissues, which is important in activating cGMP-dependent signaling pathways.
PDE9A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition.
Dorner-Ciossek et al., Biberach an der Riß, Germany. In Neurobiol Aging, 2014
Therefore, inhibition of cGMP degrading phosphodiesterases, like PDE9A, has gained interest as potential target for treatment of cognition deficits in indications like Alzheimer's disease (AD).
Phosphodiesterase 9: insights from protein structure and role in therapeutics.
Patra et al., Guwāhāti, India. In Life Sci, 2014
This review focuses on the development of drugs targeting phosphodiesterase 9A (PDE9A).
Select 3',5'-cyclic nucleotide phosphodiesterases exhibit altered expression in the aged rodent brain.
Kleiman et al., Columbia, United States. In Cell Signal, 2014
In contrast, mRNA expression of PDE1A, PDE3A, PDE3B, PDE4B, PDE7A, PDE7B, and PDE9A did not change with age.
PDE9A is expressed in the inner retina and contributes to the normal shape of the photopic ERG waveform.
Vardi et al., Philadelphia, United States. In Front Mol Neurosci, 2013
Here we tested the contribution of PDE9A to retinal processing by recording the electroretinograms (ERG) of PDE9A (™/™) (KO) mice and by localizing the enzyme.
A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease.
Altstiel et al., United States. In Curr Alzheimer Res, 2013
BACKGROUND: PF-04447943 is a potent, selective phosphodiesterase 9A (PDE9A) inhibitor that elevates guanoscine 3',5' - cyclic monophosphate (cGMP) in brain and cerebrospinal fluid.
Outcome after surgery for primary hyperaldosteronism may depend on KCNJ5 tumor mutation status: a population-based study from Western Norway.
Brauckhoff et al., Bergen, Norway. In Langenbecks Arch Surg, 2013
Our objective was to determine the mutation status of KCNJ5 and seven additional candidate genes for tumorigenesis: YY1, FZD4, ARHGAP9, ZFP37, KDM5C, LRP1B, and PDE9A and, furthermore, the surgical outcome of PA patients who underwent surgery in Western Norway.
DNA methylation profiles at precancerous stages associated with recurrence of lung adenocarcinoma.
Kanai et al., Tokyo, Japan. In Plos One, 2012
DNA hypermethylation of the ADCY5, EVX1, GFRA1, PDE9A, and TBX20 genes resulted in reduced mRNA expression in tumorous tissue samples.
Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo.
Schmidt et al., United States. In J Pharmacol Exp Ther, 2012
In vivo effects of PDE9A inhibition included reversal of the respective disruptions of working memory.
Phosphodiesterase type 9 (PDE9) in the human lower urinary tract: an immunohistochemical study.
Sasano et al., Sendai, Japan. In Bju Int, 2012
PDE9 is widely distributed in the urothelial epithelium of the human lower urinary tract and its potential roles may be different from those of PDE5.
Inhibition of phosphodiesterase 9A reduces cytokine-stimulated in vitro adhesion of neutrophils from sickle cell anemia individuals.
Conran et al., Campinas, Brazil. In Inflamm Res, 2011
Data show that PDE9A inhibitor, BAY-73-6691, significantly reduced basal and sickle cell (SCA) neutrophil adhesion; this was accompanied by decreased SCA neutrophil surface expressions of the L-selectin and CD11b adhesion molecules.
PDE9A, PDE10A, and PDE11A expression in rat trigeminovascular pain signalling system.
Kruuse et al., Glostrup, Denmark. In Brain Res, 2009
We here present, for the first time, the expression of PDE9A, PDE10A, and PDE11A in the trigeminovascular system; localisation indicates that they may have a role in pain pathways
Association study of phosphodiesterase genes in the Sequenced Treatment Alternatives to Relieve Depression sample.
McMahon et al., Bethesda, United States. In Pharmacogenet Genomics, 2009
PDE9A, is unlikely to play an important role in antidepressant outcome in this sample
Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction.
Jonas et al., Hannover, Germany. In World J Urol, 2001
The presence of mRNA transcripts specific for 14 different human phosphodiesterase isoenzymes and isoforms in human cavernous tissue was shown by RT-PCR: Three isogenes of PDEI, PDE2A and 10A, which hydrolyse cAMP as well as cGMP, the cAMP-specific PDE3A, four isogenes of PDE4, PDE7A and PDE8A, as well as cGMP-specific PDEs PDE5A and PDE9A.
share on facebooktweetadd +1mail to friends